Delayed neurotoxic complication of intracavitary bleomycin therapy for craniopharyngioma in a child who had previously undergone radiosurgery. Case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17566208.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Local administration of bleomycin for the treatment of craniopharyngioma is occasionally associated with serious regional complications. The authors report a case of a delayed neurotoxic complication associated with bleomycin treatment in a patient who had previously undergone radiosurgery. A 14-year-old boy presented with a cyst recurrence of mixed-type craniopharyngioma. An Ommaya device was placed in the thin-walled cyst, and after confirmation that the device was watertight, the patient received a total dose of 75 mg bleomycin intratumorally during a 5-week period. Six weeks after the final drug administration, the patient experienced complex partial epileptic seizures; a few days later sudden right temporal hemianopia developed. Within 5 days the patient became totally blind in his right eye, and the condition did not respond to corticosteroid therapy. Although drug-related toxic complications occur commonly during the course of intracavitary bleomycin treatment, they may also be encountered during the follow-up period. The reason for this delayed complication could have been previous radiotherapy or hypersensitivity of the tumor capsule to the drug.
Medical subject headings
- Antibiotics, Antineoplastic
- Bleomycin
- Brain Edema
- Craniopharyngioma
- Pituitary Neoplasms